



1 18 July 2024
2 EMA/CHMP/CVMP/QWP/422493/2024
3 Committee for Medicinal Products for Human use (CHMP)
4 Committee for Medicinal Products for Veterinary use (CVMP)

5 Questions and Answers regarding co-processed excipients 6 used in solid oral dosage forms (H & V)

7

Agreed by QWP (Quality Working Party)	July 2024
Adopted by CHMP for release for consultation	15 July 2024
Adopted by CVMP for release for consultation	18 July 2024
Start of public consultation	11 September 2024
End of consultation (deadline for comments)	31 December 2024

8
9

Comments should be provided using this [EUSurvey form](#). For any technical issues, please contact the [EUSurvey Support](#).

10

Keywords	co-processed excipients, dossier requirements, risk categories
----------	--

11

12 Introduction

13 While co-processed excipients (CoPEs) can offer benefits such as improved functionality, they also
14 introduce additional risks compared to using individual excipients. The use of CoPEs in pharmaceutical
15 formulations can present higher risks due to several factors: e.g. complexity of composition (inherent
16 variability, unpredictable interactions), quality control (challenges for analytical methods, batch to
17 batch consistency), formulation development (complexity of optimisation studies, challenges with
18 scaling up production) and stability issues due to combination of different materials.

19 These Q&As aim to harmonise and clarify dossier requirements for CoPEs using a risk-based approach;
20 the Q&As are applicable to human and veterinary solid oral dosage forms.

21 Retrospective application of the Q&As is not intended for marketed products, unless there are changes
22 to the formulation (e.g. introducing a CoPE or changes to the applied CoPE).



23 **1. What is a “co-processed excipient” in the context of these**
24 **Q&As?**

25 The term “co-processed excipients” (CoPEs) does not appear in the EU Regulation, directives or
26 guidelines. Different definitions of CoPEs exist among regions and stakeholders worldwide, but also the
27 excipient- and/or finished product-manufacturers themselves have been using this term differently
28 from any available definition.

29 In the context of these Q&As, a CoPE is a combination of two or more Ph. Eur. excipients, typically
30 two, which are processed together using a physical process (e.g. spray-drying) without the formation
31 of covalent bonds. CoPEs have intended functionalities such as improved compaction characteristics
32 which cannot be achieved by e.g. blending during routine manufacturing (low energy). If one or more
33 excipients are added by blending to a CoPE, the resulting blend is not considered a CoPE. The use of
34 excipients such as preservatives, antioxidants, chemical stabilisers etc. in order to prolong the shelf-life
35 or stabilise a CoPE is not accepted and is not considered a contribution to the functionality of a CoPE.

36 A CoPE is not a novel excipient, nor a finished product intermediate without active substance, nor a
37 “ready-to-use mixture” as referenced in EU Guidelines on excipients.

38 **2. How to categorise a co-processed excipient in a finished**
39 **product using a risk-based approach?**

40 The applicant/MAH needs to demonstrate that they have adequate understanding and control of the
41 finished product and its excipients. The potential impact of the CoPE characteristics on the finished
42 product should be evaluated during pharmaceutical development and an adequate control strategy
43 should be set up to ensure that the finished product is of consistent quality, safety and efficacy. The
44 regulatory expectations in terms of the quality dossier requirements depend on the considered risk of
45 the CoPE. This Q&A identifies three risk categories for the CoPE:

46 Category A - high risk CoPE

47 Category B - medium risk CoPE

48 Category C - low risk CoPE

49 **Risk factors to consider**

50 To assign one of the above-listed risk categories to a CoPE, the following risk factors should, as a
51 minimum, be considered and their impact on the risk level should be identified.

52 The applicant/MAH should identify which critical quality attributes (CQAs) of the finished product can
53 be impacted by the CoPE material attributes. In line with the principles of ICH Q8, whose principles can
54 also be used for veterinary products, CQAs are derived from the Quality Target Product Profile (QTPP)
55 of the product and as such they consider the dosage and target population. The known or potential
56 impact of the CoPE on CQAs, within the context of the finished product, such as appearance, assay,
57 content uniformity, release of the active substance, stability and impurity profile and impact on
58 bioavailability should be considered. Material attributes of the CoPE, such as function, physico-chemical
59 properties, composition of the CoPE in terms of number of excipients and additionally function of other
60 excipients included in the composition of the finished product should be considered. Some general
61 considerations are given below. Specific examples are provided in Annex I.

62 For example, the function(s) of the CoPE in the finished product should be considered, such as filler,
63 lubricant, stabiliser, surfactant, antioxidant, disintegrant, or release rate controlling agent, taking into

64 account the characteristics of the finished product and the rest of the formulation. A CoPE which
65 function(s) (such as disintegrant, surfactant or release rate controlling agent) has an impact on one or
66 more CQAs will be considered with a higher risk impact than a CoPE which has function(s) (such as
67 filler or binder) with low or no impact on the CQAs. If the formulation includes other excipients with the
68 same function(s), impacting the CQAs, the risk linked to the CoPE may be lower.

69 The impact on the critical process parameters (CPPs) should also be considered. The physico-chemical
70 characteristics of the CoPE, together with the proportion of the CoPE in the finished product, should all
71 be taken into consideration. For example, the impact of particle size, particle morphology, density and
72 flowability on the CPPs should be determined. The impact on manufacturability will be higher when the
73 CoPE is the main component of the finished product.

74 When assigning the risk category of the CoPE, it is not sufficient to only consider one risk factor alone,
75 but it is important to consider all risk factors and their relative risk levels, as they are interlinked.
76 When evaluating the impact of the CoPE on the CQA of the finished product, different factors should be
77 considered. It is recommended to start the evaluation by focusing on the function(s) of the CoPE, in
78 relation to the special characteristics of the finished product (QTTPs), taking into consideration the
79 qualitative and quantitative composition of the finished product. The impact ranking table in Annex I
80 gives some examples and guidance on how to evaluate them. See also the decision tree in Annex II.

81 **Overall risk evaluation**

82 Once the impact on CQAs (and CPPs if applicable) has been determined, the overall risk category of
83 the CoPE for the specific finished product can be established as outlined in the ICH Q9 guideline on
84 quality risk management, whose principles can also be used for veterinary products.

85 Any risk mitigation measures related to the impact of the CoPE on the finished product should be
86 described by the applicant/MAH in the risk evaluation.

87 Once the risk has been established and risk category assigned, the applicant/MAH should consult Q3 to
88 better understand the level of information to be provided in the dossier.

89 The final decision by the applicant/MAH is a case-by-case judgement, and in cases of doubts, a
90 scientific advice can be requested.

91 For human finished products the risks related to a CoPE identified through this risk evaluation can be
92 considered when evaluating the risk profile of the excipient (in this case the CoPE) carried out by the
93 finished product manufacturer, also referred to as manufacturing authorisation holder (MIAH), as part
94 of the formalised risk assessment (FRA) described in the Guidelines of 2015 on the formalised risk
95 assessment for ascertaining the appropriate good manufacturing practice for excipients of medicinal
96 products for human use. The applicant/MAH should ensure that they liaise closely with the finished
97 product manufacturer so that the risk category and the risk profile for the CoPE are aligned. The
98 manufacturing authorisation holder should then establish and document the elements of EudraLex
99 Volume 4 that it believes are needed to be in place in order to control and maintain the quality of the
100 CoPE. The FRA does not need to be submitted in the dossier.

101 For veterinary finished products, the aforementioned Guidelines do not apply.

102 **3. What are the regulatory dossier requirements to a co-**
103 **processed excipient?**

104 The dossier should include information in line with Directives, Regulations and Guidelines related to the
105 quality of finished products for human and veterinary use. Some of the relevant Guidelines are listed
106 below:

107 EU/ICH guideline Q8 (R2) on pharmaceutical development (EMA/CHMP/ICH/167068/2004), EU
108 guideline on development pharmaceuticals for veterinary medicinal products
109 (EMA/CVMP/QWP/684556/2022), EU Guideline on excipients in the dossier for application for
110 marketing authorisation of a medicinal product (R2) (EMA/CHMP/QWP/396951/2006) and EU
111 Guideline on excipients in the dossier for application for marketing authorisation for veterinary
112 medicinal products (EMA/CVMP/QWP/307647/2023).

113 EU guideline on manufacture of the finished dosage form (EMA/CHMP/QWP/245074/2015) and EU
114 guideline on Manufacture of the veterinary finished dosage form (EMA/CVMP/QWP/798401/2015).

115 Dossier requirements of particular relevance for all categories of CoPEs include:

116 **Description and Composition (3.2.P.1)**

117 The CoPE should be provided in 3.2.P.1 specifying the brand name, grade, the quantity present
118 (mg/unit and %/unit), the function and reference to relevant standard. Each individual excipient
119 included in the CoPE should additionally be listed specifying the grade, quantity (mg/unit and %/unit),
120 function and reference to relevant standard. This also applies to other excipients (e.g. stabilisers,
121 antioxidants etc.) included in single excipients forming the CoPE (allowed as per Ph. Eur.).

122 It is expected that each individual excipient included in the CoPE complies with Ph. Eur. (general
123 monographs and individual monographs).

124 **Pharmaceutical Development (3.2.P.2)**

125 Discussion of the CoPE chosen, concentration and characteristics that can influence the finished
126 product performance (e.g. stability, bioavailability) or manufacturability in relation to the respective
127 function of the CoPE and each individual excipient included in the CoPE, should be presented. The
128 intended functionalities of the CoPE - i.e. the unique properties of the CoPE - that are not achievable
129 through blending or by a special grade of *single* excipients should be discussed. It should be addressed
130 what benefits (in manufacturing and/or product quality and performance) are obtained in the finished
131 product. The presence of each individual component and its own specific contribution to the intended
132 functionalities (unique properties) of the CoPE should be explained.

133 A justification of the risk category of the CoPE based on the risk ranking and the decision tree as
134 provided in Annex I and II should be submitted taking the risk factors in Question 2 into account. In
135 addition, the risk evaluation of the risk factors mentioned in Q2 should be performed and presented by
136 the applicant in 3.2.P.2.

137 It should be demonstrated that processing of the individual excipients into the CoPE does not introduce
138 any covalent bonds but only produces a physical interaction, such as hydrogen bonding or Van der
139 Waals forces. Suitable characterisation techniques should be used to demonstrate that the chemical
140 structure of each excipient is preserved. Statements should be supported by data. When such data has
141 been published in scientific literature, a copy would be sufficient. When it is demonstrated that no
142 covalent bonds have been formed, the safety of the CoPE can be assumed to be similar to the safety of
143 the individual excipients.

144 **Description of the manufacturing process of the CoPE (3.2.P.4.):**

145 A general description of the manufacturing process of the CoPE including a flow chart should be
146 provided.

147 In case a continuous manufacturing is used, and the single excipients are not isolated during the
148 process, in-process controls should be in place to ensure that the single excipients comply with their
149 respective specification (the individual and general Ph. Eur. monograph and additional tests if any)
150 before inclusion in the CoPE. Such in-process controls should be indicated in the flow-chart.

151 **Specification for the CoPE (3.2.P.4.):**

152 An appropriate specification should be established in the dossier and should include:

- 153 • Physical characteristics, especially critical characteristics or material attributes and functionality
154 related characteristics (FRCs).
- 155 • Assay and identification of each individual excipient in the CoPE.
- 156 • Test for degradation products (total and individual impurities), unless otherwise justified.
- 157 • Purity test may be physical, chemical, biological and where relevant immunological.
- 158 • Tests for FRCs to ensure the manufacturing process was complete and did not result in a
159 mixture or incomplete CoPE.
- 160 • Where relevant, tests for elemental impurities and residual solvents.

161

162 All analytical procedures for testing of the CoPE should be adequately described in section 3.2.P.4.2,
163 including third country Pharmacopoeia (e.g. USP-NF) methods. For general methods, reference should
164 be made to Ph. Eur. where possible.

165 The analytical procedures for testing of the CoPE should be duly validated and demonstrated to be
166 suitable for the intended purpose. The documentation should be enclosed in 3.2.P.4.3.

167 All specification parameters and limits for the CoPE should be justified in section 3.2.P.4.4 (including
168 assay tests, purity tests and omission of tests such as residual solvents, elemental impurities and
169 degradation products and FRCs). The CoPE specification should be justified based on pharmaceutical
170 development of the finished product.

171 If, after thorough investigation, an assay test of each single excipient or other critical material
172 attributes of the CoPE cannot be performed on the final CoPE, additional detailed information on the
173 control of critical manufacturing steps (in-process controls or critical process parameters) may be
174 needed in the dossier to ensure consistent quality and homogeneity of the CoPE.

175 Specification for each individual excipient in the CoPE:

- 176 • If special grades are needed for the single excipients (before introducing them in the CoPE),
177 related specification parameters (e.g. particle size, viscosity, degree of polymerisation etc.)
178 should be included in addition to the reference to Ph. Eur. specific monographs in the
179 specifications for each individual excipient in 3.2.P.4.1.

180 **SmPC:**

181 For products for human use, the same principles as reflected in the Guideline on Summary of Product
182 Characteristics (SmPC guideline) and EC guideline on "Excipients in the labelling and package leaflet of

183 medicinal products for human use” for mixtures of excipients, are applicable. This means that the
184 single excipients included in the CoPEs should be listed individually.

185 For products for veterinary use, principles mentioned in the CVMP guideline on excipients and in the
186 QRD templates should be followed.

187 **3.1. The risk assessment concludes a category C (low risk CoPE)**

188 No additional dossier requirements apart from the generally applicable criteria as described above.

189 **3.2. The risk assessment concludes a category B (medium risk CoPE)**

190 The following additional requirements apply:

191 **Additional requirements to Description and Composition for category B CoPE (3.2.P.1)**

192 For excipients which are removed from the CoPE during the process (e.g. solvents, water), the
193 quantity (e.g. a range), function and reference to relevant standard should be listed (a footnote may
194 indicate absence in the final CoPE).

195 If water is used in the manufacturing process of the CoPE, the quality of the water should also be given
196 in 3.2.P.4, and it should be noted that it is expected that purified water in accordance with Ph. Eur. is
197 applied, unless justified.

198 **Additional requirements to Pharmaceutical Development for category B CoPE (3.2.P.2)**

199 Explanation of the use of a CoPE instead of using special grades of single excipients or routine
200 manufacturing processes e.g. granulation should be included. This includes development data (e.g. lab
201 scale experiments) from the finished product manufacturer and the CoPE manufacturer, unless
202 otherwise justified. This would also include explanations of the specific ratio of single excipients in the
203 CoPE.

204 Investigation of impact of changes in the amount of CoPE and each individual excipient on the CQA of
205 the finished product by laboratory trials in accordance with Pharmaceutical Development guidelines
206 requirements is encouraged.

207 Storage of a CoPE could impact FRCs and/or other specification parameters. This should be evaluated
208 during product development but stability studies are not expected to be submitted in the dossier. The
209 container closure system for the CoPE should be suitable for transport and storage.

210 **Additional requirements to Description of the manufacturing process for category B CoPE** 211 **(3.2.P.4.):**

212 Detailed description of the manufacturing process of the CoPE, including description of process
213 parameters, in-process controls and process evaluation of the manufacturing process of the proposed
214 batch size ranges including:

- 215 • A flow-chart should be provided with all unit operations and each individual in-process control
216 listed at each stage.
- 217 • Description of the manufacturing process (e.g. critical process parameters) should be given at
218 such a level that the finished product manufacturer is able to make a risk assessment and
219 justify that no new unqualified degradation products are formed under the actual
220 manufacturing conditions.

221 • Demonstration that a sufficiently homogenous CoPE quality (all relevant quality attributes) is
222 obtained throughout the entire process via appropriate process parameters and in-process
223 controls. A specific assay of each individual excipient should be provided as part of the
224 demonstration.

225 **Information on the name and address of the manufacturer of the category B CoPE**
226 **(3.2.P.4.1):**

227 Information on the name and address of the CoPE manufacturer.

228 **3.3. The risk assessment concludes a category A (high risk CoPE)**

229 In addition to the above listed requirements, when a category A CoPE is part of the finished product
230 composition, the requirements described in the European scientific guidelines on the quality of human
231 or veterinary finished products should be considered. Deviations from guidelines should be explained
232 and justified.

233 **Annex I: Risk factors and impact ranking table**

234 Risk factors are interconnected and should not be considered in isolation. The risk factors provided below should all be considered but are not exhaustive.

235 Numbers and percentages mentioned in the table have been derived from the experience gained so far when reviewing finished product containing CoPEs
 236 and should be considered example values only. For simplicity, only examples of high and low impact are presented. However, it is acknowledged that the
 237 level of risk is continuum (i.e. not binary and spans between low, medium and high) and the MAH could identify a medium risk level.

238

	Impact on CQAs of the finished product	
Material attributes of the CoPE	Impact level - High	Impact level - Low
Function(s) of the CoPE		
CoPE function(s) as defined in 3.2.P.1 (e.g. filler, lubricant, stabilisers, antioxidant, disintegrant, surfactant or release rate controlling agent)	Critical functions with high impact on finished product CQAs (e.g. disintegrant, surfactant). The higher the number of critical functions the higher the risk.	Function with low effect on finished product CQA (e.g. filler or binder).
Function of rest of the other excipients included in the composition of the finished product	e.g. finished product contains a CoPE with critical function(s) and other excipients with functions which have low impact the CQAs (e.g. filler), the risk is considered higher.	e.g. risk level is reduced when the finished product contains an excipient with same function as the CoPE and thereby impacting the same CQA.
Physico-chemical characteristics of the CoPE		
Physico-chemical characteristics having an impact on the CQAs of the finished product (e.g. characteristics having an impact on appearance, assay, content uniformity, stability and impurity profile of the finished product and bioavailability, such as particle morphology particle size, amorphous content, solvents, process related impurities, degradation products etc.)	e.g. Particle morphology, surface area, pore size distribution, particle size, amorphous content impacting dissolution have a high risk e.g. a CoPE with impurities that may have an impact on the degradation of the finished product is considered as high risk.	e.g. Particle morphology, Particle size not impacting bioavailability has a low risk with respect to this CQA. e.g. a CoPE that does not have a negative impact on the stability of the finished product is considered to have a low risk with respect to this CQA.
CoPE composition		
Number of excipients in CoPE	≥4 The higher the number of excipients having different functions and/or physico-chemical characteristics, the higher is the risk as it may become increasingly difficult to achieve consistent quality related to the characteristics of each individual excipient	2 The risk linked to the CoPE variability is lower if the number of excipients in the CoPE is low.

	of the CoPE and to control the quality of the CoPE.	
Proportion of CoPE in the formulation: percentage of CoPE in respect to the entire formulation of the finished product.	Impact level - High	Impact level - Low
If the CoPE material attributes have low or medium impact on CQA:	>75% If the CoPE has low or medium impact on CQAs, it is the main component in the formulation and the proportion is high, then the risk is high.	<50% If the CoPE has low or medium impact on CQAs, and other excipients in the formulation have high impact on the CQA, then the risk is low.
If the CoPE material attributes have high impact on CQA:	>30% This risk needs to be taken into consideration with the CoPE impact on CQAs and the rest of the formulation: if the CoPE has an impact on CQAs, its proportion is high and no other excipients impact the same CQAs, then the impact is high.	<15% If the CoPE has an impact on the CQAs but the same CQA is also controlled by other excipients and the proportion of the CoPE is low, then the risk is low.

239

240 Example on classification (Category A, High Risk)

241 Pharmaceutical form: **modified release tablet**

242 Composition of the finished product:

<i>Function</i>	<i>Amount</i>
Active substance	15%
CoPE (retarding agent) Retarding agent/Viscosity modifying agent Pore former/disintegrant Surfactant Glidant	45%
Filler	39%
Glidant	0.25%
Lubricant	0.75%

243

244

245

Risk factor and impact ranking based on Annex I and Annex II.

<p>Has the function of the CoPE excipient a high impact on the FP CQAs? Yes, high risk as the CoPE has multiple functions and is a retarding agent (pore former and viscosity modifying) and disintegrant with impact on the CQA dissolution and bioavailability.</p>	<p>YES →</p>	<p>Have the physico-chemical characteristics of the CoPE a high impact on CQAs of the finished product? Yes, high risk as the physico-chemical characteristics of CoPE such as pore size distribution and particle morphology have impact on CQA dissolution.</p>	<p>YES →</p>	<p>Number of excipients in CoPE Four (4) excipients in CoPE thus high risk as ≥ 4.</p>	<p>≥ 4 →</p>	<p>Proportion of CoPE in the finished product The CoPE is 45% of the formulation (high proportion) and thus, high risk as $>30\%$.</p>	<p>$>30\%$ →</p>	<p>High Indicates that the Category may end as A. High risk, and CoPE in this finished product is Category A.</p>
---	------------------	---	------------------	--	----------------------------------	--	------------------------------------	---

246

247 Example on classification (Category B, Medium Risk)

248

249 Pharmaceutical form: **Hard capsules**

250

251 Composition of the finished product:

<i>Function</i>	<i>Amount</i>
Active substance	45%
CoPE (solubility enhancer) Surfactant Mineral carrier	2%
Diluent	48%
Disintegrant	4%
Lubricant	0.5%
Glidant	0.5%

252

253 Risk factor and impact ranking based on Annex I and Annex II.

254

Has the function of the CoPE excipient a high impact on the FP CQAs? Yes, high risk as the CoPE is a solubility enhancer with impact on the CQA dissolution and bioavailability	YES →	Have the physico-chemical characteristics of the CoPE a high impact on CQAs of the finished product? Yes, high risk as the physico-chemical characteristics of CoPE (pore size distribution and particle morphology) with impact on CQA dissolution.	YES →	Number of excipients in CoPE Two (2) excipients in CoPE thus lower risk.	2 →	Proportion of CoPE in the finished product The CoPE is 2% of the formulation and is <15%.	<15% →	Medium, Indicates that the Category may end as B. Medium risk, and CoPE in this finished product is Category B.
--	----------	---	----------	---	--------	--	-----------	--

255

256 Example on classification (Category C, Low Risk)

257

258 Pharmaceutical form: **film-coated tablet**

259

260 Composition of the finished product:

Function	Amount
Active substance	15%
CoPE (Filler) Filler Disintegrant	60%
Super disintegrant	5%
Filler	19%
Lubricant	1%

261

262 Risk factor and impact ranking based on Annex I and Annex II.

263

<p>Has the function of the CoPE excipient a high impact on the FP CQAs? No, lower risk. The function of the CoPE is filler/disintegrant and another excipient in the formulation has major impact on same CQA dissolution.</p>	NO →	<p>Have the physico-chemical characteristics of the CoPE a high impact on CQAs of the finished product? No, lower risk.</p>	NO →	<p>Number of excipients in CoPE Two (2) excipients in CoPE thus lower risk.</p>	2 →	<p>Proportion of CoPE in the finished product The CoPE is 60% of the formulation and therefore 50% < %CoPE < 75%.</p>	50% < %CoPE < 75% →	<p>Low Indicates that the Category may end as C. Lower risk, and CoPE in this finished product is Category C.</p>
--	---------	---	---------	---	--------	---	------------------------	--

264

Annex II: Decision tree on risk factor and impact ranking of CoPE with regard to the CQAs of the finished product

The risk factors in Q2 and risk level described in Risk factors and Impact Ranking table (Annex I) should be considered when deciding on the impact of the CoPE material attributes on the CQAs of the finished product. Numbers and percentages mentioned in the decision tree have been derived from the experience gained so far when reviewing finished product containing CoPEs and should be considered example values only.

For simplicity only impact high and low are considered in the decision tree; however, it is acknowledged that a medium impact can be identified. The final decision will be taken on case by case basis.

